Similarly, TP53 co-alterations were associated with lower ORRs in a cohort of patients with urothelial carcinoma and FGFR3 alterations treated with erdafitinib under real-world conditions40; however, in the FIGHT-201 study in FGFR-altered bladder cancer28, baseline concurrent TP53 alterations did not correlate with response or nonresponse to pemigatinib, cautioning against overgeneralization of subgroup analyses. The gene discussed is FGFR3; the disease is urothelial carcinoma.